10
May
2022

MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Candid Therapeutics Emerges with $370M to Develop T-Cell Engagers for Autoimmunity
Marea, Incubated by Third Rock, Gets $190M to Take Aim at Remnant Cholesterol
Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
MOMA Gets Roche Deal, $66M Upfront, to Discover Novel Small Molecule Cancer Drugs